Karen L. Smith - 02 Jul 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SKYE	Director Stock Option (Right to Buy)	Award	$0	+40,000		$0.000000	40,000	02 Jul 2024	Common Stock	40,000	$7.56	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The stock option will vest in equal monthly installments over the one year period from the date of grant.